Frequently Asked Questions and Answers
Tobacco Regulatory Science (R01 Clinical Trial Optional) RFA-OD-19-028

Updated August 27, 2019

1. What does the “clinical trials” option mean for my study?
   A. Note that the National Institutes of Health (NIH) defines a clinical trial as “a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.” As this definition can apply to studies that investigators may not have previously considered to be a “clinical trial,” we highly recommend investigators review the resources available at https://grants.nih.gov/policy/clinical-trials/definition.htm. Located at this site are Case Studies, Frequently Asked Questions (FAQs), and a Decision Tree that will help determine if your investigation is considered a clinical trial or not. Additionally, investigators are encouraged to discuss proposals and research ideas with the appropriate scientific research contacts listed in Section VII of the funding opportunity announcement (FOA) to which you plan on applying.

2. How is RFA-OD-19-028 different from RFA-OD-19-019 (R01 clinical trial optional)?
   A. The following are the main differences in RFA-OD-19-028:
      • There are eight scientific interest areas instead of seven: chemistry and engineering has been added to the reissued FOA. In addition, toxicity, addiction, health effects, behavior, communications, marketing influences, and impact analysis have some new research priorities in their description.
      • The definition of product characteristic has been expanded in the reissued FOA. The term "characteristic" encompasses materials, ingredients (including additives, nicotine carrier, nicotine formulations and flavors), design, composition, heating source, and other features of a tobacco product, including harmful and potentially harmful constituents. Product characteristics can be incorporated into all the topics above.

3. Can non-funded applications from RFA-OD-19-019 (R01 clinical trial optional) be resubmitted to this FOA as -A1 resubmission applications?
   A. Yes. However, applicants must meet all applicable criteria for RFA-OD-19-028.

Eligibility for the R01
4. Are foreign institutions eligible to apply?
   A. Yes. However, research proposed in applications from foreign institutions must be specific to the U.S. population and provide information that will be useful to U.S. regulations.
5. Are foreign individuals eligible to apply as Principal Investigators (PIs) for this FOA?
A. The intent of this FOA is to develop a cadre of new investigators in the early stages of establishing independent careers in tobacco regulatory research. Foreign individuals are eligible to apply but must demonstrate that the proposed research can directly contribute to the U.S. Food and Drug Administration’s (FDA) regulatory authority over the manufacture, marketing, and distribution of tobacco products. Individuals must also demonstrate that they will be employed by an eligible institution for the full award period of the grant.

Budget
6. Is there a budget cap on R01 applications?
A. Yes. R01 budgets submitted to this funding announcement are limited to $300,000 in direct costs per year. Three years maximum.

Application Requirements/Submission
7. Where can the applicant find additional information regarding application submission?
A. The NIH provides multiple resources for applicants with submission questions. Below is a list of resources, depending on the type of question being asked:

- For questions regarding Grants.gov registration and submission, as well as downloading forms and application packages, please contact Grants.gov Customer Support at support@grants.gov.
- For questions regarding application instructions, process, and finding additional NIH grant resources, please contact GrantsInfo at GrantsInfo@nih.gov.
- For questions regarding ASSIST, eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, and postsubmission issues, please contact Finding Help Online. Telephone: 301-402-7469 or 866-504-9552 (toll free).
- For peer review questions, contact Dr. Weijia Ni from the Center for Scientific Review at niw@csr.nih.gov.
- For financial/budgetary questions, please contact the appropriate grants management contact listed in Section VII of the FOA.
- For scientific and responsiveness questions, please contact the appropriate scientific contact listed in Section VII of the FOA.

8. Am I required to submit a letter of intent (LOI)?
A. An LOI is not required, and it does not enter into the review process. However, it allows NIH staff to estimate the potential review workload and plan the review. We suggest sending the LOI 60 days before the application due date. Investigators are encouraged to communicate with NIH scientific research contacts to discuss their research ideas and specific aims prior to submitting applications, as all proposed research-specific aims must be within the regulatory authority of the FDA Center for Tobacco Products (CTP) in order to be deemed responsive to this FOA. Applications that are non-responsive will not be reviewed.
Suggested content of LOI:

- Descriptive title of proposed activity
- Name(s), address(es), and telephone number(s) of the Program Director(s) (PD(s))/PI(s)
- Names of other key personnel
- Participating institution(s)
- Number and title of this funding opportunity
- Specific aims

9. Where do I send the LOI?
   A. The letter may be sent by email to: TRSP@mail.nih.gov
      Or by regular mail to:
      Tobacco Regulatory Science Program
      Office of Disease Prevention
      6100 Executive Boulevard
      Room 3B01, MSC 7530
      Bethesda, MD 20892-7530 (Use Rockville, MD 20852 for Express Mail)
      Tel: 301-451-7464
      Fax: 301-480-2230

Responsiveness

10. How do I know if my application is responsive to this FOA?
   A. This is a critical question, as each of the specific aims in the application must meet the following criteria to be considered responsive. The project must:

      - Address one or more of the eight interest areas listed in the FOA, and
      - Fall within the scope of the FDA CTP’s regulatory authority.

As such, applicants are strongly encouraged to contact the scientific research contacts listed in Section VII of the FOA for feedback about responsiveness prior to submitting an application.

Note that upon receipt, applications will be evaluated for responsiveness by the FDA CTP and participating NIH Institutes. Only applications that are within the scope of the eight areas listed in the FOA and the FDA CTP’s regulatory authority will be peer reviewed. Your application title, abstract, and specific aims are used to make this determination, so it is important that you are clear about your proposed scientific aims and how they may potentially inform the FDA CTP’s regulatory authority. Staff reviewing your application will refer to other parts of the application if responsiveness is unclear based on title, abstract, and specific aims. If your application is deemed responsive, it will undergo scientific peer review by experts convened specifically for this FOA (by the NIH Center for Scientific Review). If your application is deemed non-responsive, it will be withdrawn prior to evaluation of its scientific merit, i.e., peer review.
11. The FDA CTP has regulatory authority over the manufacture, marketing, and distribution of tobacco products. What are some examples of these authorities?
A. The Family Smoking Prevention and Tobacco Control Act gave the FDA responsibility and authority to, among other things:
   • Restrict cigarettes and smokeless tobacco retail sales to youth.
   • Restrict the sale and distribution of tobacco products, including advertising and promotion, as appropriate to protect public health.
   • Review modified risk tobacco products, such as those marketed for use to reduce harm, prior to their introduction to the market.
   • Adjust warning labels for cigarettes and smokeless tobacco products in order to promote greater public understanding of the risks of tobacco use.
   • Establish standards for tobacco products (for example, setting limits on harmful and potentially harmful constituents and nicotine levels) as appropriate to protect the public health.
   • Review new tobacco products prior to their introduction to the market.
For more information, see “Family Smoking Prevention and Tobacco Control Act - An Overview.”

12. What are the research interest areas for this FOA?
A. This FOA is focused on the following eight FDA CTP interest areas. Only applications proposing research projects relevant to one or more of these eight areas will be considered for funding:
   1. Chemistry and engineering
   2. Toxicity
   3. Addiction
   4. Health effects
   5. Behavior
   6. Communications
   7. Marketing influences
   8. Impact analysis

13. Are the eight research priorities in the FOA listed in order of priority to the FDA, or are they of equal priority?
A. The research priorities are not listed in priority order. They are of equal priority to the FDA CTP.

14. For the purpose of this FOA, how is reproductive health defined under the health effects scientific interest area?
A. Reproductive health refers to the diseases, disorders, and conditions that affect the functioning of the male and female reproductive systems during all stages of life.
15. May researchers include foreign populations in their proposed research?
   A. Foreign populations may be included if the product under study is the same as the one(s) used in the United States. Results from foreign populations must be relevant to the U.S. population and U.S. regulation of tobacco.

16. In general, what areas of research are **not within the FDA CTP’s regulatory authority**?
   A. The Family Smoking Prevention and Tobacco Control Act gives the FDA the authority to regulate the manufacture, marketing, and distribution of tobacco products to protect public health and to reduce tobacco use by youth. In general, the FDA CTP’s regulatory authorities do NOT extend to the following:
      • Setting tax rates for tobacco products
      • Regulating therapeutic products, such as those marketed to treat tobacco dependence (regulated by other parts of FDA)
      • Setting clean indoor air policies
      • Regulating tobacco growing
      • Requiring the reduction of nicotine yields to zero
      • Providing cessation services
      • Banning all cigarettes, smokeless tobacco products, little cigars, other cigars, pipe tobacco, or roll-your-own tobacco products
      • Changing the minimum age to purchase tobacco products

17. What topics are non-responsive to this FOA?
   A. Although the following research topics may be within FDA CTP’s regulatory authority to fund, they are not to be included in the FOA and will be deemed out of scope and not reviewed:
      • Studies of short-term health effects and/or acute topography/clinical pharmacology testing of early generation ENDS products
      • Mechanistic studies (i.e., basic science of disease development) unless biomarkers of harm with predictive value for disease development associated with tobacco product use is an outcome
      • Short-term studies of the acute effects of reduced nicotine content cigarettes
      • Graphic health warnings for cigarette packages and advertisements
      • Communicating harmful and potentially harmful constituents to the public
      • Impacts of marketing restrictions on adults
      • Descriptive studies of demographics and/or risk perceptions that describe only exposure to advertising without linking exposure to tobacco use behaviors

18. Is a research proposal in which the primary outcome identifies differential effects of various tobacco products on disease risk, incidence, or progression of disease considered responsive?*
   A. Yes. A proposal identifying differential effects of various tobacco products on disease would be responsive. Examples* might include:
      • Pulmonary function-testing outcomes following use of various combustible tobacco products.
• Oral manifestations following use of various tobacco products, especially new and emerging tobacco products.

* The examples provided are illustrative and should not be viewed as definitive or comprehensive.

19. Within the scientific domains of “toxicity” or “health effects,” is a research proposal which investigates the mechanisms and/or etiology of tobacco-related disease responsive?

A. It depends. Mechanistic and/or etiologic research is largely relevant to disease prevention or treatment, neither of which is within the FDA CTP’s regulatory authority, so would not be considered responsive. These types of research may in some cases be responsive, but only if the outcomes of the research inform the mandate of the FDA CTP. For example, research comparing the mechanistic processes or underlying disease etiology of different tobacco products or their constituents may be considered responsive. As such, it is important to discuss your research concept with an NIH scientific research contact and to consider submitting an LOI.

20. Within the scientific domains of “addiction,” toxicity,” or “health effects,” is a treatment intervention study designed to compare the effectiveness of various tobacco products on tobacco cessation considered responsive?

A. No. The FDA CTP’s regulatory authority does not extend to regulating therapeutic uses of tobacco products as this authority rests with other Centers within the FDA. Examples of research projects that would be considered responsive include: (1) an observational study to examine the natural history of whether participants quit smoking cigarettes while using a different tobacco product, and (2) assessing if communications regarding the health consequences of using tobacco products have an impact on usage rates.* In many of its key regulatory areas, the FDA CTP is charged with assessing the impact of tobacco products on the health of the population as a whole, taking into account both users of tobacco products and persons who do not currently use tobacco products—as well as the increased or decreased likelihood that existing users of tobacco products will stop using such products, and the increased or decreased likelihood that those who do not use tobacco products will start using such products.

* The examples provided are illustrative and should not be viewed as definitive or comprehensive.

21. Within the scientific domains of “toxicity” or “health effects,” is a research proposal in which the primary outcome informs treatment of disease considered responsive?

A. No. The FDA CTP does not regulate products or support development of clinical interventions intended for the treatment of disease. For example, pharmacotherapy for treatment of cancer or emphysema, screening, physical activity, or dietary interventions for heart disease would all be considered non-responsive.*

* The examples provided are illustrative and should not be viewed as definitive or comprehensive.
22. What types of biomarker research may be appropriate for FDA CTP funding?
   A. Proposals identifying biomarkers of specific tobacco product exposure and/or disease and those with the potential to differentiate exposure of differing tobacco products could be considered responsive.

   Examples* include:
   
   - Biomarkers to measure exposure to new and emerging tobacco products.
   - Biomarkers of disease (e.g., cancer, cardiovascular disease, pulmonary disease, and reproductive and developmental effects) that can be associated with specific measures of tobacco exposure.
   - Development of a non-clinical biomarker of disease coupled with traditional toxicology and/or pharmacology studies to provide a relevant framework for the regulatory application.
   - Studies linking biomarkers of disease in non-clinical models that translate to biomarkers that are measurable in the clinical setting.
   - Magnitude of changes in biomarkers that translates into clinically meaningful impacts on human health outcomes.

   Biomarker research may fall within the scope of one or more of the eight interest areas, depending on the intended use of the biomarker. However, there is research that will remain outside of FDA CTP authorities such as biomarker research for which the primary focus is to inform treatment.

   * The examples provided above are illustrative and should not be viewed as definitive or comprehensive.

23. What types of research on nicotine and/or nicotinic receptors are appropriate for consideration of funding by the FDA CTP?
   A. If the research provides information on outcomes such as motor activity, memory, or neuronal responses to particular ligands, the research is likely not appropriate. Research to rapidly screen tobacco constituents for activity at the nicotinic receptor to determine their dependence potential would be considered responsive.*

   * The examples provided above are illustrative and should not be viewed as definitive or comprehensive.

24. Are studies on the impact of state and local tobacco control policies responsive?
   A. It depends upon the specific policies being examined and whether they fall under the purview of the FDA CTP. Studies evaluating the impact of a tobacco tax increase are not responsive, as the FDA CTP does not have regulatory authority regarding tax rates on tobacco products. Similarly, the FDA CTP does not have authority over the sale of tobacco cessation medications. For example, a study evaluating the effectiveness for tobacco cessation of providing free nicotine replacement therapy would not be considered responsive. Studies evaluating the impact of a tobacco advertising restriction, a ban on the sale of flavored tobacco products, or restrictions on the sale of single serving products, however, may be considered responsive.*

   * The examples provided above are illustrative and should not be viewed as definitive or comprehensive.
25. Are public opinion polls about tobacco regulations responsive to FDA CTP regulatory authorities?
   A. Unlike state or local policymaking, where public support can be an important factor in the adoption and implementation of policies, public opinions cannot be used to support federal regulations.

26. Is the FDA CTP interested in graphic health warning research given that the U.S. government did not seek Supreme Court review of the court decision that blocked the implementation of graphic health warnings on cigarette packages and advertising?
   A. No, as indicated in the non-responsive research topics in the FOA, studies on graphic health warnings for cigarette packages and advertisements are not allowed. However, the FDA is committed to funding and conducting research on graphic health warnings on alternative tobacco products.

27. What topics are considered responsive within the scientific domain of “impact analysis”?
   A. The following types of analyses are examples* of topics that would be considered responsive under “impact analysis”:
      • Computational/mathematical modeling and simulation and/or statistical modeling of the public health impact of potential FDA/CTP action.
      • Health and economic impact of tobacco use and/or tobacco regulatory policies on vulnerable populations.
      • Economic burden (e.g., healthcare cost, productivity loss) of tobacco-related diseases on users and non-users (e.g., secondhand and thirdhand exposure).
      • Studies evaluating the impact of tobacco regulatory actions (e.g., mandated changes in product characteristics) on consumer behavior or behavioral intentions.

* The examples provided above are illustrative and should not be viewed as definitive or comprehensive.

28. Will applications that propose to study products not yet available in the United States be considered responsive?
   A. Yes, if the product(s) meets the statutory definition of a “tobacco product” under the Tobacco Control Act (i.e., any product made or derived from tobacco and intended for human consumption, including any component, part, or accessory of a tobacco product), then studies examining these products could be considered responsive to the FOA. However, the application must demonstrate that the proposed research can directly contribute to the FDA’s regulatory authority over the manufacture, marketing, and distribution of tobacco products within the United States. As the relevance may be dependent on not only the product, but also the types of research being conducted, we recommend that you discuss any particular proposed research with one or more of the scientific research contacts listed in Section VII of the FOA.
29. Would an application that proposed to study a heat-not-burn product that is already included in a modified-risk tobacco product (MRTP) application be considered responsive?

A. Potentially, yes. While heat-not-burn products would be considered a “tobacco product” under the Tobacco Control Act and would fall under the regulatory authority of the FDA CTP as a result of the deeming rule, both the responsiveness of a research proposal investigating this product and its relevance to the FDA CTP priorities would depend upon the type of research being proposed. As such, we recommend that you discuss any particular proposed research with one or more of the scientific research contacts listed in Section VII of the FOA.

30. The FOA states that “short-term studies of the acute effects of reduced nicotine content cigarettes” would be deemed non-responsive to the FOA. What does this FOA consider “short-term”?

A. There is no specific timeframe that defines “short-term” or acute outcomes. However, the appropriate length for any study is dependent upon the research question. Applicants are encouraged to familiarize themselves with the funded research and published literature in this area through the NIH, the Tobacco Regulatory Science Program (TRSP), and other CTP-supported tobacco regulatory research and see how their proposed research could expand on the current understanding of reduced nicotine cigarette use.

31. What are some special considerations when preparing applications?

A. The following are some special considerations when preparing applications.

- **Data Harmonization for Tobacco Regulatory Research via the PhenX Toolkit:** NIH and FDA encourage investigators involved in human-subjects studies to employ a common set of tools and resources that will promote the collection of comparable data across studies and to do so by incorporating the measures from the Core and Specialty collections, which are available in the Tobacco Regulatory Research Collection of the PhenX Toolkit.

- **Tobacco Industry Funding of Applicants:** The FDA CTP has adopted the following guidance regarding tobacco industry funding of applicants responding to this FOA.

  - The National Advisory Council on Drug Abuse (NACDA) has set forth points with regard to existing or prospective sponsored research agreements with tobacco companies or their related entities and the impact of acceptance of tobacco industry funding on National Institute on Drug Abuse’s (NIDA) credibility and reputation within the scientific community. Please see NIDA points to consider for details. While this guidance was originally issued for NIDA applicants, it is relevant for all applications submitted under this FOA.

  - **Recommended Guidelines for the Administration of Drugs to Human Subjects:** NACDA also recognizes the importance of research involving the administration of drugs with abuse potential, and dependence or addiction liability, to human subjects. Potential applicants are encouraged to obtain and review these recommendations of Council before submitting an application that will administer compounds to human subjects. The guidelines are available on NIDA's Web site at https://archives.drugabuse.gov/advisory-council-minutes/nacda-guidelines-administration-drugs-to-human-subjects.
Review

32. Will more weight be assigned in the review for applications that address more than one of the eight priority areas?
   A. No. Reviewers will be looking to see if the research question is addressed adequately and appropriately. When approaching which research priorities to address, we recommend that investigators think about what scientific evidence the FDA would need to support a product review process or regulatory decision.

33. On what basis are applications selected for funding?
   A. Applications will be selected for funding based on scientific merit, current availability of funds, and FDA CTP current research priorities.

Post-Award Management and Reporting

34. Which NIH Institute/Center (IC) will manage my award?
   A. It depends on the nature and scope of the research projects proposed. Applicants may request assignment to a particular IC in their cover letter, but the NIH will make the final determination regarding IC assignment.

35. Are the reporting requirements for these awards the same as other NIH grants?
   A. No. A mid-period progress report will be due every 6 months following the project start date, as well as the annual progress report and all reports required by the NIH at the time of grant close-out.

36. Are policies and procedures different for these awards?
   A. Yes. This includes exclusion from Streamlined Noncompeting Award Process (SNAP) and all carryover requests requiring prior approval from both the NIH and the FDA CTP.

37. Some researchers are under limitations with respect to accepting funds from the tobacco industry. How will these FDA research awards be funded?
   A. As mandated in the Tobacco Control Act, the FDA is authorized to collect fees from tobacco product manufacturers and importers for its activities related to the regulation of the manufacture, distribution, and marketing of tobacco products. Although the tobacco user fees are specified in statute, Congress must actually appropriate the funds before the FDA can obligate them. The tobacco industry has no control over FDA CTP funding decisions. The FDA uses some of these funds to award research grants.

38. What will be the availability of confidential information obtained by the FDA, for example, product and constituent reporting?
   A. Several laws govern the confidentiality of tobacco product information submitted to the FDA, including sections 301(j) and 906(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the Trade Secrets Act, and the Freedom of Information Act, as well as the FDA’s implementing regulations. The FDA’s general regulations concerning the public availability of FDA records are contained in 21 CFR Part 20. Regarding the reporting of constituents, the FD&C Act requires tobacco product manufacturers and importers to
report quantities of harmful and potentially harmful constituents (HPHCs) in tobacco products or tobacco smoke by brand and sub-brand. The FD&C Act also directs the Agency to publish a list of HPHCs by brand and by quantity in each brand and sub-brand, in a format that is understandable and not misleading to a layperson.

39. If a scientific study proposes to make ANY change to a commercialized tobacco product (e.g., manipulating the size of the product; putting the tobacco product in different colored packaging), then an investigational tobacco products (ITP) request is recommended by the FDA (Reference: Draft Guidance Use of Investigational Tobacco Products). What information is required in the ITP request?

A. The information needed in an ITP request may vary depending on the proposed ITP and the type of study. The FDA needs to determine whether the product is a tobacco product, whether the tobacco product is within our current jurisdiction, whether the tobacco product is an ITP, and whether the study products will be provided to human subjects. For example, if one makes a change in labeling of a commercially marketed tobacco product and it will not be used by human subjects, no ITP request is needed. If one makes a change in labeling of a commercially marketed tobacco product and there will be actual use by human subjects, then the FDA recommends that an ITP request come to the FDA CTP for review; but it is likely that chemistry, engineering, and manufacturing will not be needed. If you have questions about ITP, please contact Debbie Cordaro (debbie.cordaro@fda.hhs.gov).

Research Resources

40. What is the PhenX Toolkit, and why does the FOA encourage its use?

A. The PhenX Toolkit is a web-based catalog of freely-available standard measures that can be easily incorporated into research studies. The measures span many scientific domains, and include Specialty Collections in Tobacco Regulatory Research (TRR). As noted in NOT-OD-17-034, the TRR Collections provide a common set of recommended measures that, when incorporated across studies, will facilitate data sharing, comparing, and integration, as well as replication and validation of findings. The measures that are included in the PhenX Toolkit were identified by working groups of experts within each of the scientific domains, followed by outreach to the relevant scientific communities to establish a consensus for the prioritized, recommended measures. PhenX measures are typically well-established, broadly validated measures that are low-burden to the participant and investigator. The TRR Collections include standard measures like the Fagerstrom Test for Nicotine Dependence and questions found in large and/or nationally representative surveys like the Population Assessment of Tobacco and Health (PATH) and the National Youth Tobacco Survey (NYTS). For more information about the TRR Collections in the PhenX Toolkit, see the TRSP website.

41. Will NIDA nicotine research cigarettes (NRCs) be available for research funded through this FOA on a similar basis as currently?

A. Yes. NRC Spectrum Cigarettes will be available for these awards and research investigators need to prepare a request package. Please visit the Nicotine Research Cigarettes Drug Supply Website for more information and to learn about the request process. For further questions, email NIDANRCSupply@mail.nih.gov and specify NRC in the subject line.
42. Might it be possible to obtain other research tobacco products (e.g., cigars, roll-your-own tobacco or e-cigarettes) with known nicotine concentrations for use in research funded through this FOA?

A. At this time, we are aware of one additional research tobacco product, the standardized research e-cigarette (SREC) developed by NIDA, NIH. Unlike the SPECTRUM combustible cigarette provided by NIDA to researchers at no cost, the SREC was developed under a small business contract issued by NIDA to NJOY, LLC. Consequently, researchers will purchase the SREC directly from NJOY. Researchers with NIH funding to use the SREC are guaranteed to be able to purchase the devices; however, there is no expectation that NJOY will be limiting access to the SREC. For more information and how to request SREC click here.

NIH Guide FOA:
Tobacco Regulatory Science (R01 Clinical Trial Optional)

NIH-FDA Tobacco Regulatory Science Program website:
http://prevention.nih.gov/tobacco/